Amanda Corbel
Manager, Communications Office
Email amanda.corbel@nih.gov or call 301-228-4489 for all media related questions.
New rapid assay developed to support medicine trial for blood cancers
Scientists developed a new, precise assay to detect cancer-driving mutations in myeloMATCH precision medicine trials.POSTED: 9/10/2025
New method for detecting HIV drug resistance may lead to improved therapies
Scientists developed a bioinformatics pipeline to more accurately detect HIV drug resistance and potentially improve the quality of antiretroviral therapies for people living with HIV.POSTED: 8/18/2025
Monoclonal antibody is effective in targeting pancreatic cancer cells
Scientists developed a monoclonal antibody (mAb) that selectively targets pancreatic cancer cells. This is an early step toward new treatments for a deadly malignancy that is the third leading cause of cancer deaths. POSTED: 8/14/2025
‘Pan-KRAS’ drug aiming at KRAS-related cancers lacking targeted therapies now being tested in humans
BBO-11818 is now in clinical trials may one day be a targeted treatment for KRAS-driven cancers. POSTED: 7/14/2025
Laboratory develops clinical assay for recurrent thyroid cancer
CLIA Molecular Diagnostics Laboratory developed and validated a blood test to detect recurrent thyroid cancer following surgical removal of the gland.POSTED: 7/10/2025
The allele-specific lipid sensing of KRAS mutants
KRAS mutants don’t just anchor to membranes—they choose their lipid partners. Discover how this specificity could unlock new cancer therapies.POSTED: 7/8/2025
Advancing global cervical cancer research: HPV Serology Laboratory completes eight-year mission
HPV Serology Laboratory and its research network have developed and established International Standards for antibodies to seven types of HPV.POSTED: 6/17/2025
Frederick National Laboratory teams help evaluate plant virus’ preclinical safety as cancer treatment
Teams found that repeat injections with a plant virus--cowpea mosaic virus (CPMV)--may safely activate the immune system for cancer therapy.POSTED: 6/12/2025
Pioneering biophysicist, computational biologist elected to the National Academy of Sciences
Head of the Basic Science Program's Computational Structural Biology Section was elected to the National Academy of Sciences.POSTED: 5/29/2025
ASCO oral presentation, posters to explore use of liquid biopsy in rare cancers
Biswajit Das, Ph.D., MoCha associate director, will present this study in an oral abstract session on Friday, May 30 at 4:45 CT in Hall D1 of the convention center. Using ctDNA to classify tumor types In another study, scientists evaluated the ctDNA to determine fragmentation patterns, which are unique to each tumor type and can help more precisely identify the cancer. The fragment-based model accurately identified the cancer type in nearly 100% of samples that were definitively diagnosed in pathology. About 5% of the time, patient samples are determined “not otherwise specified (NOS)” in pathology reports. The tumor’s origin is unknown, or the sub-type of a cancer cannot be determined. Using the fragmentation data, Peter Wu and colleagues accurately identified sub-types of pancreatic and ovarian cancer, indicating ctDNA could be used as a tool to more precisely classify tumor types. MoCha Director Chris Karlovich, Ph.D., will present the study in POSTED: 5/28/2025
Looking for more?
Explore our scientific publications
Our researchers publish hundreds of papers each year in various peer-reviewed journals, including Science, Nature, and The New England Journal of Medicine.